Johnson & Johnson raises outlook as second-quarter earnings top estimates

Traders Union
All News
Financial News
J&J raises Q2 outlook

Highlights

Johnson & Johnson’s Q2 revenue rises 6.6% year over year to $25.31 billion, exceeding the $25.05 billion LSEG consensus, with adjusted EPS at $2.90 versus $2.85 estimates.
The company increases its full-year earnings guidance, with the midpoint widening by more than the Q2 beat, signaling management’s confidence in sustained performance.
Pharmaceutical business drives global sales up 7.8% and oncology portfolio posts 17.3% growth, offsetting MedTech weakness as overall MedTech sales grow 4.5% despite cardiovascular softness.

Second-quarter results and guidance outlook

As reported by CNBC, Johnson & Johnson says second-quarter revenue rises 6.6% year over year to $25.31 billion, topping the LSEG consensus of $25.05 billion, while adjusted earnings per share reach $2.90 versus estimates of $2.85.

The company also raises its full-year guidance, with the midpoint of the earnings outlook increasing by more than the size of the second-quarter beat. That suggests management sees the quarter's strength as sustainable rather than temporary.

Shares fall more than 2% in afternoon trading on Tuesday, even as the results come in mostly ahead of expectations. The market reaction follows a period in which healthcare names such as Johnson & Johnson move in and out of favor as investors rotate between AI-linked growth stocks and defensive sectors.

Pharma strength offsets MedTech weakness

Drug operations remain the main driver of growth. Johnson & Johnson says its pharmaceutical business grows worldwide sales 6.8% on an operational basis and 7.8% on a reported basis, and more than 14% excluding Stelara, which has lost patent protection and is facing biosimilar competition.

The cancer portfolio posts 17.3% growth, helped by nearly 50% growth in Carvykti, 19% growth in Darzalex and nearly 57% growth in Tecvayli. Lung cancer drug Rybrevant also grows more than 61%, and CEO Joaquin Duato says during the second quarter the company asks the FDA to expand its license to include head and neck tumors.

In MedTech, cardiovascular sales weaken as Abiomed heart pump sales slump, but the broader segment still expands. Johnson & Johnson reports worldwide MedTech sales growth of 3.6% on an operational basis and 4.5% on a reported basis, indicating that softer cardiovascular performance is partly offset by stronger results across the rest of the portfolio.

The company also continues to highlight its product pipeline, including Icotyde, an oral IL-23 inhibitor approved in March for moderate-to-severe plaque psoriasis. Management's stronger guidance and continued drug momentum support the view that steady execution, rather than short-term earnings reactions, remains the key driver for the stock.

Our previous report on Congress’ review of FDA reforms examined how lawmakers are weighing regulatory modernization to strengthen U.S. leadership in biomedical innovation. It highlighted the FDA’s Operation Trialblazer initiative to reduce regulatory ambiguity and speed development through modern trial designs and real-world evidence, alongside the upcoming FDA user-fee reauthorization that could broaden into wider streamlining and investment incentives.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.